Modern Healthcare News
 
RSS feed

Gilead Sciences news and information

Magazine
Sovaldi fuels earnings jump for Gilead
By Virgil Dickson | July 26, 2014 | Print Magazine Print Magazine Subscription Details
Gilead Sciences' second-quarter earnings blew through year-ago levels, thanks in part to its blockbuster, controversial hepatitis C drug Sovaldi.
FULL STORY »
 

News
Gilead reports massive Q2 earnings jump thanks to Sovaldi
By Virgil Dickson | July 23, 2014 | Basic Web Basic Web Subscription Details
Gilead Science's second-quarter earnings blew through year-ago levels, thanks in part to its blockbuster, and controversial, hepatitis C drug Sovaldi.
FULL STORY »
 

Information
HIV pills show more promise to prevent infection
By Associated Press | July 22, 2014
There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.
FULL STORY »
 

News
Senators want answers about Sovaldi's price tag
By Paul Demko | July 11, 2014 | Basic Web Basic Web Subscription Details
Sens. Ron Wyden (D-Ore.), chairman of the Finance Committee, and Chuck Grassley (R-Iowa), the ranking minority member of the Judiciary Committee, sent a letter Friday to the chairman and CEO of Sovaldi manufacturer Gilead Sciences with questions about how the drug's price was determined.
FULL STORY »
 

News
Reform makes cash tight for providers, but not pharma and payers
By Bob Herman | June 20, 2014 | Basic Web Basic Web Subscription Details
Hospitals and other providers face more financial challenges, and perhaps more near-term credit downgrades, than health insurers and pharmaceutical companies as healthcare reform unfolds, according to a new report from Standard & Poor's.
FULL STORY »
 


Advertisement | View Media Kit

News
Reform Update: Pricey hepatitis C drugs strain Medicaid budgets
By Virgil Dickson | June 17, 2014 | Basic Web Basic Web Subscription Details
State officials are scrambling to control the burden of Gilead's $1,000-a-pill hepatitis drug Sovaldi, particularly in states that have agreed to cap Medicaid spending under CMS waivers.
FULL STORY »
 

News
CMS targets boomers, those at high risk for hepatitis C screenings
By Virgil Dickson | June 02, 2014 | Basic Web Basic Web Subscription Details
The CMS has finalized its coverage decision to reimburse for hepatitis C virus screenings for two target populations, including baby boomers.
FULL STORY »
 

News
AstraZeneca holding firm against Pfizer's advances
By Beth Kutscher | May 23, 2014 | Basic Web Basic Web Subscription Details
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...
FULL STORY »
 

News
Excessive drug costs could invite price caps: AHIP's Ignagni
By Paul Demko | May 21, 2014 | Basic Web Basic Web Subscription Details
The steep cost of Sovaldi—Gilead Sciences' $1,000-per-pill treatment for hepatitis C—is prompting wide-ranging discussions about the cost of drugs and whether the government should take more steps to regulate the cost of potentially life-saving treatments.
FULL STORY »
 

News
HIV prevention pill guidelines issued by CDC
By Steven Ross Johnson | May 15, 2014 | Basic Web Basic Web Subscription Details
Health officials Wednesday issued guidelines for the use of a pill to prevent HIV infection among those at high risk of contracting the disease.
FULL STORY »
 

Search ModernHealthcare.com:


 

Switch to the new Modern Healthcare Daily News app

For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.